Metabolic Characterization of a Putative Novel Antidiabetic Drug, GTI-421
Abstract
The purpose of this project is to define and characterize a novel putative metabolic therapy. Specifically we seek to characterize a compound, GTI-421, which inhibits hepatic glucose transport by establishing the therapeutic efficacy of GTI-421, and define its mechanism of action. The premise of this project is that hepatic glucose transporter (GLUT) blockade mimics the beneficial effects of generalized fasting. Finding a GLUT inhibitor is therefore expected to enhance hepatic and extrahepatic metabolism through canonical fasting response pathways. We have made significant strides toward our stated goals during this reporting period. Our major objectives and advances as they relate to these advances are described herein.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2018
- Accession Number
- AD1055801
Entities
People
- Brian J DeBosch
Organizations
- University of Washington